Latest News & Updates
Dr. Anne Marie Salapatek, CSO at Inflamax Research, will be presenting clinical trial data demonstrating the utility of Environmental Exposure Chambers in asthma and allergic rhinitis research at upcoming 2014 European Respiratory Society conference in Munich, Germany, September 6-10.
Inflamax Research Inc., a full-service CRO, announced today that their Chief Science Officer, Dr. Anne Marie Salapatek, will be presenting clinical trial data demonstrating how Environmental Exposure Chambers (EECs) can be utilized for the development of clinical trial programs aimed at showing safety and efficacy without the need for costly, large scale field studies.
The data being presented, across three poster presentations, is a representation of study design types that demonstrates how baseline allergic rhinitis symptoms can be provoked consistently out of allergy season. Patients are treated with an investigational or already-approved product, and then provoked again post-treatment to determine...Read Full Story
Dr. Anne Marie Salapatek, President & Chief Scientific Officer of Inflamax Research, will be presenting results of a meta-analysis outlining statistically significant correlations between house dust mite symptoms in the traditional Field trial approach and those collected from patients in the Environmental Exposure Chamber (EEC). These findings support the use of EEC allergen challenge approach for pivotal testing.
Dr. Salapatek, an internationally renowned scientist with expertise in allergy, asthma and EEC clinical trials, is an invited speaker at the EAACI meeting. “This data shows that conducting studies in the EEC provides the best research option that reduces the variability seen in field trials whilst providing an accurate read of a therapy’s efficacy, and importantly also which well reflects that seen in the traditional field trial approach”, states Dr. Salapatek. These findings are to be presented at the 2014 The European Academy of Allergy and Clinical Immunology (EAACI) Congress in Copenhagen, Denmark on June 10th at 1:30 pm.
Dr. Salapatek will also be presenting a poster demonstrating that correlations between skin prick tests (SPT) and specific IgE levels in patients vary...Read Full Story
Released October 24, 2013
The CDM team has experience with electronic data capture services, having built, released, and “locked” 375
databases since 2006 in multiple study designs and therapeutic areas. All team members are members of the
Society for Clinical Data Management (SCDM) and all have achieved their Certified Clinical Data Manager
The utilization of CDISC and CDASH standards provides the industry-standard data exchange
models which facilitates submission for FDA requirements. In addition to a full complement of data
management services, including web-based fully compliant 21 CFR Part 11 electronic data capture capability
via secure Internet access, Inflamax Research Inc. has integrated its e-Source data capture in the clinic
seamlessly into good data management practices...Read Full Story
Released July 9, 2013
OmniComm Systems, Inc. (OTC: OMCM), one of the fastest growing companies in the Electronic Data Capture (EDC) marketplace, today announced that Inflamax Research, a full service Contract Research Organization (CRO), has made a 5 year commitment to utilize OmniComm’s eClinical SuiteTM to further enhance their clinical operations.
The OmniComm eClinical Suite is a comprehensive, functionally-rich solution that streamlines clinical trial processes and supports DDE and EDC within one system. It utilizes proven workflows that enable clinical operations to effectively...Read Full Story
Released May 21, 2013
Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation.
Inflamax Research today announces a collaboration with the Immune Tolerance Network (ITN), which is funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH), to conduct clinical research into the underlying mechanisms of allergy.
Inflamax scientists worked closely with internationally renowned expert scientists of the ITN to design the study, which will provide critical insight into the usefulness of two key clinical models used in the study of allergy treatments, the Environmental Exposure Chamber (EEC) and Nasal Allergen Challenge (NAC) models. Although both the models are well recognized and supported by numerous publications, to date no direct comparison between the allergic responses evoked by them has been performed... Read Full Story
Released April 9, 2013
Inflamax Research Chosen to Conduct a Multicenter Environmental Exposure Chamber Phase 3 Study of Ultrashort Grass Allergy Vaccine by Allergy Therapeutics (UK) Ltd.
Inflamax Research Inc. today announced that it has been selected by Allergy Therapeutics (UK) Ltd. (ATL) (AGY:LSE), as the CRO to conduct ATL’s pivotal Phase III study for Grass MATAMPL product for US-FDA registration.
The study will involve the location of mobile EEC at centers in three metropolitan areas in the US Midwest, US North East and in Canada, with several investigative sites at each node contributing subjects to the study. The screening and dosing will take place at the investigator site and the subject will be sent to the mobile EEC, located close to the investigator site, for EEC related activities.
Inflamax will operate the... Read Full Story
Read All News at Inflamax Research
Released February 18, 2013
Inflamax Research Inc., a specialty Clinical Research Organization focused on allergy and asthma research utilizing their Next Generation Environmental Exposure Chamber (EEC) technology, today announced the appointment of Dr. Anne Marie Salapatek as President & CSO.
Dr. Salapatek is an internationally renowned scientist with expertise in allergy, asthma and EEC clinical trials. Previously she was the Principal Scientist at Cetero Research (formerly Allied Research International) where she was responsible for the development and validation of new Allergy and Asthma clinical models, advising clients on study designs including utilizing EEC technology for seasonal and perennial allergies, asthma, non-allergic rhinoconjunctivitis and COPD. Dr. Salapatek has worked with many... Read Full Story